CD28 and type 1 diabetes mellitus: Also TNFR2 agonism in T1D is unique in expansion to create homogenous populations of these desired Treg cells unlike the standard protocols of anti-CD3 plus anti-CD28, IL2 and rapamycin that expand but as demonstrated in Figure 5d, expand heterogenous CD4 cells populations, not only highly activated Tregs.